Safety
primary malignancies
ADVERSE EVENTS
The safety population of the study, defined as patients who received at least one dose of study treatment, consisted of 212 patients in the Ven-Obi arm and 214 in the Clb-Obi arm. The median follow-up time was 66.7 months in the Ven-Obi arm and 67.6 months in the Clb-Obi arm. The majority of patients in both arms completed study treatment per protocol (Supplementary Fig. Serious adverse events (SAE) occurred in 127 (59.9%) of patients in the Ven-Obi arm and 102 (47.7%) in the Clb-Obi arm (Supplementary Tables Second primary malignancies were observed in 27 (12.7%) of patients in the Ven-Obi arm and 16 (7.5%) in the Clb-Obi arm (Supplementary Table 